These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30537217)

  • 1. Treatment-resistant PLA2R-negative membranous nephropathy responsive to low-density lipoprotein apheresis.
    Szymanski JM; Waldman M; Conry-Cantilena C; West KA
    J Clin Apher; 2019 Aug; 34(4):495-498. PubMed ID: 30537217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-density lipoprotein apheresis for PLA2R-related membranous glomerulonephritis accompanied by IgG4-related tubulointerstitial nephritis.
    Nishizawa Y; Honda K; Aoyama Y; Hosoda Y; Tamura T; Horimoto A; Omae K; Higuchi C; Sakura H; Nitta K; Ogawa T
    CEN Case Rep; 2020 Nov; 9(4):395-403. PubMed ID: 32557252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Low-Density Lipoprotein Apheresis for Nephrotic Idiopathic Membranous Nephropathy as Initial Induction Therapy.
    Koshi-Ito E; Koike K; Tanaka A; Watanabe Y; Kamegai N; Shimogushi H; Shinjo H; Otsuka Y; Inaguma D; Takeda A
    Ther Apher Dial; 2019 Dec; 23(6):575-583. PubMed ID: 30993827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China.
    Guo N; Cao Y; Dai H; Yuan L; Shi L; Zhang Y
    Med Sci Monit; 2019 Dec; 25():9364-9368. PubMed ID: 31813930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of low-density lipoprotein-apheresis on nephrotic syndrome due to membranous nephropathy in renal allograft: a case report.
    Ideura T; Hora K; Kaneko Y; Yamazaki T; Tokunaga S; Shigematsu H; Kiyosawa K
    Transplant Proc; 2000 Feb; 32(1):223-6. PubMed ID: 10701029
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor.
    Jatem Escalante E; Segarra Medrano A; Carnicer Cáceres C; Martín-Gómez MA; Salcedo Allende MT; Ostos Roldan H; Agraz Pamplona I
    Nefrologia; 2015; 35(5):479-86. PubMed ID: 26306972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Membranous nephropathy: New insights in therapeutic approach].
    Dahan K
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy.
    Kumar V; Ramachandran R; Kumar A; Nada R; Suri D; Gupta A; Kohli HS; Gupta KL; Jha V
    Nephrology (Carlton); 2015 Aug; 20(8):572-5. PubMed ID: 26194981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membranous nephropathy complicated by immune thrombocytopenia treated with low-density lipoprotein apheresis: a case report and literature review.
    Nishizawa K; Yamashita T; Ogawa Y; Kobayashi H
    CEN Case Rep; 2022 Feb; 11(1):43-49. PubMed ID: 34287815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.
    Provatopoulou S; Kalavrizioti D; Stangou M; Kouri MN; Kalliakmani P; Papasotiriou M; Papachristou E; Goumenos DS; Papagianni A
    Rom J Intern Med; 2019 Jun; 57(2):141-150. PubMed ID: 30864406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
    Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
    Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
    Segarra-Medrano A; Jatem-Escalante E; Quiles-Pérez MT; Salcedo MT; Arbós-Via MA; Ostos H; Valtierra N; Carnicer-Cáceres C; Agraz-Pamplona I
    Nefrologia; 2014 May; 34(3):353-9. PubMed ID: 24798555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-density lipoprotein apheresis therapy for steroid- and cyclosporine-resistant idiopathic membranous nephropathy.
    Sato Y; Tsunoda S; Nozue T; Pan Q; Wakasugi H; Yoshimura A
    Intern Med; 2012; 51(18):2597-602. PubMed ID: 22989833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases.
    Radice A; Pieruzzi F; Trezzi B; Ghiggeri G; Napodano P; D'Amico M; Stellato T; Brugnano R; Ravera F; Rolla D; Pesce G; Giovenzana ME; Londrino F; Cantaluppi V; Pregnolato F; Volpi A; Rombolà G; Moroni G; Ortisi G; Sinico RA
    J Nephrol; 2018 Apr; 31(2):271-278. PubMed ID: 29081027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis?
    Muso E; Yashiro M; Matsushima M; Yoshida H; Sawanishi K; Sasayama S
    Nephrol Dial Transplant; 1994; 9(3):257-64. PubMed ID: 8052431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Treatment of Patients With Refractory PLA
    Klomjit N; Fervenza FC; Zand L
    Am J Kidney Dis; 2020 Dec; 76(6):883-888. PubMed ID: 32311405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).
    Radice A; Trezzi B; Maggiore U; Pregnolato F; Stellato T; Napodano P; Rolla D; Pesce G; D'Amico M; Santoro D; Londrino F; Ravera F; Ortisi G; Sinico RA
    Autoimmun Rev; 2016 Feb; 15(2):146-54. PubMed ID: 26527329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus.
    Segarra-Medrano A; Jatem-Escalante E; Carnicer-Cáceres C; Agraz-Pamplona I; Salcedo MT; Valtierra N; Ostos-Roldán E; Arredondo KV; Jaramillo J
    Nefrologia; 2014; 34(4):491-7. PubMed ID: 25036063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy.
    Hoxha E; Kneißler U; Stege G; Zahner G; Thiele I; Panzer U; Harendza S; Helmchen UM; Stahl RA
    Kidney Int; 2012 Oct; 82(7):797-804. PubMed ID: 22673885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Low-density Lipoprotein Apheresis in a Patient with Refractory Idiopathic Membranous Glomerulonephritis.
    Yabuuchi J; Suwabe T; Mizuno H; Ueno T; Hoshino J; Sekine A; Kawada M; Yamanouchi M; Hayami N; Hiramatsu R; Hasegawa E; Sawa N; Takaichi K; Fujii T; Ohashi K; Ubara Y
    Intern Med; 2017; 56(12):1543-1547. PubMed ID: 28626181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.